Loading...
NPI 1447314513 · Linden, NJ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ammon Analytical Laboratories LLC is a clinical medical laboratory provider located in Linden, New Jersey. This profile covers 14 Medicare and 76 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Ammon Analytical Laboratories LLC |
| Address | 35 E Blancke St |
| City | Linden |
| State | NJ |
| ZIP | 07036 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 21, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $98.8M |
| Medicare | $276.3K |
Payer mix is heavily skewed toward Medicaid: lifetime Medicare revenue is $276.3K compared with $98.8M in Medicaid, so the provider is effectively a Medicaid-scale operation rather than a Medicare-focused lab. This imbalance indicates Medicaid is the primary commercial relationship and revenue driver for the business.
The service line is concentrated on presumptive and definitive drug testing: Medicare top codes are 80307, G0483 and G0482 and Medicaid top codes are 80307, G0480 and G0481, reflecting a operations model built around high-volume toxicology screening (80307) and confirmatory GC/MS or LC/MS definitive testing (G0480–G0483). The code mix signals a laboratory structured to handle both large-volume screening and more complex confirmatory analyses rather than routine chemistry panels or anatomic pathology.
Revenue concentration is high in both payers: the top 3 Medicare codes by revenue account for 83.7% of the provider's total Medicare revenue, and the top 3 Medicaid codes by revenue account for 84.1% of the provider's total Medicaid revenue. That concentration shows a narrow set of services (primarily drug testing) producing the vast majority of billings and creates dependency on utilization of those specific code families.
At the state level the provider is a dominant Medicaid drug‑testing vendor: 80307 shows 775.4K claims and $39.5M revenue (40.2% of this provider's total Medicaid revenue) and ranks #3 of 151 in-state (99th percentile; extreme outlier, far above typical state volume). Similarly, G0480 reports 311.1K claims and $28M revenue (28.4% of Medicaid revenue) and ranks #3 of 110 in-state (98th percentile; extreme outlier), and G0481 reports 123.9K claims and $15.2M revenue (15.5% of Medicaid revenue) and ranks #2 of 39 in-state (97th percentile; notably above typical state volume). These positions indicate outsized market share and volume concentration in New Jersey for Medicaid toxicology services.
By contrast, the provider’s Medicare presence is modest in absolute revenue and described as typical for many national peers: Medicare total is $276.3K with 80307 generating $128.6K (46.5% of Medicare revenue) and ranking #106 of 4760 nationally (98th percentile; typical, unremarkable volume for this code). Other Medicare definitive-testing codes such as G0483 ($52.3K, 18.9%) and G0482 ($50.5K, 18.3%) sit in mid-range national percentiles (68th and 78th respectively) and are characterized as typical, unremarkable volume, indicating the provider is not a dominant national Medicare lab despite high Medicaid scale.
The provider also bills non‑toxicology lab services and pandemic-era testing at materially smaller scale: Medicaid includes U0003 with 42.7K claims and $2.9M revenue (2.9% of Medicaid revenue) and a range of immunoassays and panels (e.g., 86803, 80053, 85025) that together comprise minor revenue shares. These secondary lines suggest the lab supports broader community testing needs but remains primarily defined by its toxicology throughput.
Tenure is long-standing: the NPI was enumerated 2006-12-21 (~20 years ago), indicating an established operational history in the market. That longevity, paired with the concentrated Medicaid volumes, supports the conclusion that AMMON ANALYTICAL LABORATORIES LLC has built a sustained, specialized service footprint in New Jersey’s public payer space.
From a competitive and contracting perspective, the data identify this provider as a major Medicaid partner for drug-testing services in-state and a modest national Medicare participant. Payers considering network participation or utilization oversight should account for the provider’s state-level volume dominance in 80307 and G0480 and the strong revenue concentration in a narrow set of toxicology codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
14 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,110 | $60 | $128.6K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 220 | $240 | $52.3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 260 | $200 | $50.5K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 170 | $150 | $25.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 150 | $110 | $16.7K |
| 86803 | Qualitative or Semiquantitative Immunoassays; Hepatitis C antibody | 50 | $10 | $740 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 60 | $10 | $550 |
| 87340 | The lab analyst performs a test to detect hepatitis B surface antigen, also called HBsAg, using an immunoassay technique, such as EIA. | 50 | $10 | $480 |
| 86707 | The lab analyst performs an immunoassay to evaluate the patient’s specimen, typically serum, for hepatitis Be antibody. | 30 | $10 | $320 |
| 86709 | The lab analyst performs an immunoassay to evaluate the patient’s serum for antibodies to hepatitis A, specifically immunoglobulin M, or IgM. | 30 | $10 | $320 |
Showing 1–10 of 14
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
14 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 14 | 40 | 60 | $240 | $134.7K |
| G0480 | 31 | 50 | 260 | $110 | $91.8K |
| G0482 | 13 | 60 | 120 | $190 | $74.2K |
| G0481 | 26 | 60 | 110 | $150 | $64.8K |
| 80307 | 9 | 100 | 310 | $60 | $59.5K |
| 80053 | 340 | 560 | 90 | $10 | $50.8K |
| 86803 | 19 | 30 | 130 | $10 | $36K |
| 85027 | 67 | 80 | 100 | $10 | $29.2K |
| 85025 | 569 | 750 | 120 | $10 | $24.2K |
| 87340 | 17 | 20 | 110 | $10 | $18.3K |
Showing 1–10 of 14
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
76 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 775,450 | $50 | $39.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 311,150 | $90 | $28M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 123,940 | $120 | $15.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 52,770 | $120 | $6.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 42,250 | $110 | $4.5M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 42,660 | $70 | $2.9M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 16,300 | $20 | $326K |
| 86803 | Qualitative or Semiquantitative Immunoassays; Hepatitis C antibody | 14,550 | $20 | $232.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 3,550 | $60 | $202.2K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 5,250 | $30 | $178.4K |
Showing 1–10 of 76
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
76 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 25 | 130 | 3,180 | $60 | $4.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 30 | 2,020 | $110 | $2M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 34 | 40 | 590 | $20 | $1.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3 | 150 | 3,680 | $30 | $1.5M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 40 | 1,690 | $70 | $1.4M |
| 86480 | The lab analyst performs a test to evaluate a cell mediated immunity gamma interferon antigen response to certain tuberculosis, or TB, antibodies. | 20 | 40 | 810 | $30 | $1.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 37 | 70 | 4,800 | $50 | $1M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 33 | 120 | 900 | $20 | $971.9K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 26 | 120 | 940 | $20 | $957.4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 110 | 1,810 | $50 | $930.1K |
Showing 1–10 of 76
Other providers in the same ZIP code as Ammon Analytical Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Accu Reference Medical Lab, LLC | NJ | Clinical Medical Laboratory | $21.2M | $183M |
| Bettercare Home Health Services, LLC | NJ | Home Health Agency | $0 | $30.3M |
| Medexpress Urgent Care - Northern New Jersey, PC | NJ | Urgent Care Clinic/Center | $0 | $13.8M |
| Five Star Adult Medical Day Care Center LLC | NJ | Adult Day Care Clinic/Center | $0 | $10.8M |
| Preet Randhawa | NJ | Cardiovascular Disease Physician | $351.4K | $0 |
| David Rojer | NJ | Orthopaedic Surgery Physician | $290.4K | $0 |
| Dariusz Nowak | NJ | Endocrinology, Diabetes & Metabolism Physician | $215K | $0 |
| Julio Diaz | NJ | Internal Medicine Physician | $202.9K | $0 |
| Maria Silva-khazaei | NJ | Specialist | $176.1K | $0 |
| Paul Verona | NJ | Diagnostic Radiology Physician | $157.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.